Serina Therapeutics (SER) Income from Continuing Operations (2018 - 2026)
Serina Therapeutics (SER) posted Income from Continuing Operations of 6379000.0 for Q4 2025, up 0.58% sequentially from 6416000.0 in Q3 2025, and down 7.95% YoY from 6930228.17 in Q4 2024.
Serina Therapeutics (SER) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Serina Therapeutics has reported Income from Continuing Operations for 8 years, with the latest figure at 6379000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 7.95% year-over-year to 6379000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 25042000.0 (down 33.03% YoY) and the FY2025 annual result came in at 19215000.0, down 71.46% from the prior year.
- Income from Continuing Operations grew to 6379000.0 in Q4 2025 per SER's latest filing, from 6416000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 435000.0 in Q4 2023 and troughed at 6416000.0 in Q3 2025.
- A 5-year average of 3266150.0 and a median of 2546500.0 in 2021 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations soared 124.41% in 2023, then slumped 1458.39% in 2024.
- Over 5 years, Income from Continuing Operations stood at 2262000.0 in 2021, then climbed by 21.22% to 1782000.0 in 2022, then surged by 124.41% to 435000.0 in 2023, then plunged by 1458.39% to 5909000.0 in 2024, then fell by 7.95% to 6379000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 6379000.0, 6416000.0, and 5956000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Serina Therapeutics | 46.70 Mn | 23.67 Mn | - | -6.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.73 Mn |
| Dec 31, 2025 | -6.38 Mn |
| Sep 30, 2025 | -6.42 Mn |
| Jun 30, 2025 | -5.96 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | -5.91 Mn |
| Sep 30, 2024 | -5.43 Mn |
| Jun 30, 2024 | -4.48 Mn |
| Mar 31, 2024 | -3.00 Mn |
| Dec 31, 2023 | 435,000.00 |
| Sep 30, 2023 | -1.56 Mn |
| Jun 30, 2023 | -1.05 Mn |
| Mar 31, 2023 | -1.05 Mn |
| Dec 31, 2022 | -1.78 Mn |
| Sep 30, 2022 | -2.44 Mn |
| Jun 30, 2022 | -2.62 Mn |
| Mar 31, 2022 | -2.71 Mn |
| Dec 31, 2021 | -2.26 Mn |
| Sep 30, 2021 | -1.96 Mn |
| Jun 30, 2021 | -2.48 Mn |